(Q40222732)

18 September 2017

title

Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice (English)

1 reference

18 September 2017

0 references

11

Michael S Diamond

0 references

Norbert Nowotny

7

object named as

Norbert Nowotny

0 references

Luisa Barzon

8

object named as

Luisa Barzon

1 reference

18 September 2017

10

Sebastian Ulbert

1 reference

18 September 2017

6

Justin M Richner

1 reference

18 September 2017

Sofia E Magnusson

1

1 reference

18 September 2017

Karin H Karlsson

2

1 reference

18 September 2017

Jenny M Reimer

3

1 reference

18 September 2017

Silke Corbach-Söhle

4

1 reference

18 September 2017

Sameera Patel

5

1 reference

18 September 2017

Karin Lövgren Bengtsson

9

1 reference

18 September 2017

Linda Stertman

12

1 reference

18 September 2017

language of work or name

English

0 references

publication date

28 December 2013

1 reference

18 September 2017

1 reference

18 September 2017

volume

32

1 reference

18 September 2017

issue

7

1 reference

18 September 2017

page(s)

800-808

1 reference

West Nile Virus: biology, transmission, and human infection

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

West Nile virus infection and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Explosive spread of a neuroinvasive lineage 2 West Nile virus in Central Europe, 2008/2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Emerging viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Pathogenesis of West Nile Virus Infection: a Balance between Virulence, Innate and Adaptive Immunity, and Viral Evasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Preparation and immunogenic properties of a recombinant West Nile subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Immunogenicity and Protective Efficacy of a Recombinant Subunit West Nile Virus Vaccine in Rhesus Monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

A live, attenuated recombinant West Nile virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Immunization of mice against West Nile virus with recombinant envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Current status and potential application of ISCOMs in veterinary medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Iscoms Containing PurifiedQuillajaSaponins Upregulate both Th1-like and Th2-like Immune Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

T-helper 1 cells elicited by H5N1 vaccination predict seroprotection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Induction of Epitope-Specific Neutralizing Antibodies against West Nile Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Inactivated West Nile Virus (WNV) vaccine, Duvaxyn WNV, protects against a highly neuroinvasive lineage 2 WNV strain in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Complement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

CD8+ T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Antibody responses in humans infected with newly emerging strains of West Nile Virus in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.12.030

10.1016/J.VACCINE.2013.12.030

7 January 2021

Identifiers

DOI

1 reference

18 September 2017

1 reference